Current Report Filing (8-k)
December 07 2016 - 8:04AM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of report (date of earliest event
reported): December 7, 2016
TONIX PHARMACEUTICALS HOLDING CORP.
(Exact name of registrant as specified
in its charter)
Nevada
|
001-36019
|
26-1434750
|
(State or Other Jurisdiction
of Incorporation)
|
(Commission
File Number)
|
(IRS Employer
Identification No.)
|
509 Madison Avenue, Suite 306, New York,
New York 10022
(Address of principal executive offices)
(Zip Code)
Registrant’s telephone number,
including area code:
(212) 980-9155
Copy of correspondence to:
Marc J. Ross, Esq.
James M. Turner, Esq.
Sichenzia Ross Ference Kesner LLP
61 Broadway
New York, New York 10006
Tel: (212) 930-9700 Fax: (212) 930-9725
Check the appropriate box below if the
Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions
(see General Instruction A.2. below):
¨
Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨
Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨
Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨
Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
On December 7, 2016, Tonix Pharmaceuticals
Holding Corp. (the “Company”) will present a poster entitled
“The AtEase Study: A Phase 2 Multicenter Randomized
Clinical Trial of the Safety and Efficacy of TNX-102 SL in the Treatment of Military-Related PTSD”
(the “Poster”),
at the 55
th
Annual Meeting of the American College of Neuropsychopharmacology being held in Hollywood, Florida. The
Poster will be presented by Dr. Gregory Sullivan, M.D., Chief Medical Officer of the Company. This Poster replaces the prior version
of a poster that the Company filed on a Form 8-K on December 2, 2016.
The foregoing description of the Poster
is qualified in its entirety by reference to the Poster, a copy of which is filed as Exhibit 99.01 to, and is incorporated
by reference in, this report.
The information in this Current Report
is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934
or otherwise subject to the liabilities of that Section. The information in this Current Report shall not be incorporated by reference
into any registration statement or other document pursuant to the Securities Act of 1933, except as shall be expressly set forth
by specific reference in any such filing.
|
Item 9.01
|
Financial Statements and Exhibits.
|
|
99.01
|
The AtEase Study: A Phase 2 Multicenter Randomized Clinical Trial of the Safety and Efficacy
of TNX-102 SL in the Treatment of Military-Related PTSD
Poster*
|
* Furnished
herewith.
SIGNATURE
Pursuant to the requirement
of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned
thereunto duly authorized.
|
TONIX PHARMACEUTICALS HOLDING CORP.
|
|
|
|
Date: December 7, 2016
|
By:
|
/s/ BRADLEY SAENGER
|
|
Bradley Saenger
|
|
Chief Financial Officer
|
Tonix Pharmaceuticals (NASDAQ:TNXP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Tonix Pharmaceuticals (NASDAQ:TNXP)
Historical Stock Chart
From Apr 2023 to Apr 2024